Abstract
The incidence of malignant melanoma has greatly increased in recent years (1). Proper tumor staging is a key prerequisite for choosing the appropriate treatment strategy in oncology in general and this is equally true for melanoma (2). While the cross-sectional imaging modalities sonography, computed tomography (CT) and magnetic resonance imaging (MRI) are sensitive to morphologic changes identification of tumor tissue e. g. in normal sized lymph nodes is difficult with these methods (3). Furthermore, morphological imaging procedures are better used to evaluate a given region of the body than the entire body. A single imaging modality with the potential to distinguish accurately between benign and malignant lesions, and to define the extent of disease would be extremly helpful in the evaluation and management of malignant melanoma.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Skolnick A.A. (1991) Melanoma epidemic yields grim statistics. JAMA 265,3217–3218.
Horgan K, Hughes LE. (1993) Review. Staging of melanoma. Clin Radio! 48, 297–300.
Buzaid AC, Sandler AB, Maani S, et al. (1993) Role of computed tomography in the staging of primary melanoma. J Clin Oncl 11, 638–643.
Warburg O. (1931) The metabolism of tumors. New York: Richard R. Smith, Inc., 167–181.
Hatanaka M. (1974) Transport of sugars in tumor cell membranes. Biochem Biophys Acta 355, 77–104.
Weber G. (1977) Enzymology of cancer cells (part 2). N Engl J Med 296, 541–555.
Kubota K, Kubota R, Yamada S. (1993) FDG accumulation in tumor tissue. Glycolysis and cancer cells. J Nucl Med 34, 419–421.
Som P, Atkins HL, Bandoypadhyay D, et al. (1980) A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 21, 670–675.
Dahlbom M, Hoffmann EJ, Hoh CK, et al. (1992) Whole body positron emission tomography: part I. Methods and performance characteristics. J Nucl Med 33, 1191–1199.
Hoh CK, Hawkins RA, Glaspy JA, et al. (1993) Cancer detection with whole-body PET using 2-[18F] fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 4, 582–589.
Gritters LS, Francis IR, Zasadny KR and Wahl RL. (1993) Initial assessment of positron emission tomography using 2-fluorine-18fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 34, 1420–1427.
Choi Y, Brunken RC, Hawkins RA, et al. (1991) Determinats of myocardial glucose utilization assessed with dynamic FDG PET [abstract]. Circulation 84, 1690.
Cherry SR, Dahlbom M, Hoffman EJ. (1991) 3D PET using a conventional multislice tomograph without septa. J Comput Assist Tomogr 15, 655–668.
Bailey D.L. (1992) 3D acqisition and reconstruction in positron emission tomography. Ann Nucl Med 6, 123–130.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Steinert, H.C. (1998). Clinical Application of Whole-Body [18F]-FDG-PET in Malignant Melanoma. In: Gulyás, B., Müller-Gärtner, H.W. (eds) Positron Emission Tomography: A Critical Assessment of Recent Trends. NATO ASI Series, vol 51. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4996-9_17
Download citation
DOI: https://doi.org/10.1007/978-94-011-4996-9_17
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6097-4
Online ISBN: 978-94-011-4996-9
eBook Packages: Springer Book Archive